Erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,
has clinical activity in advanced lung cancer, but disease that initially responds to erlotinib …

Activating mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain
determine responsiveness to EGFR tyrosine kinase inhibitors in patients with advanced non …

Non–small cell lung cancer patients carrying oncogenic EGFR mutations initially respond to
EGFR-targeted therapy, but later elicit minimal response due to dose-limiting toxicities and …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and
erlotinib, are effective for non‐small cell lung cancer with activating EGFR mutations …

Overexpression and mutational activation of the epidermal growth factor receptor (EGFR) is
involved in tumor development and progression in non-small-cell lung cancer (NSCLC) …

Lung cancer leads cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC),
the most prevalent subtype of this recalcitrant cancer, is usually diagnosed at advanced …

Patients with lung cancer with activating mutations in the EGF receptor (EGFR) kinase, who
are treated long-term with tyrosine kinase inhibitors (TKI), often develop secondary …

Purpose: Agents inhibiting the epidermal growth factor receptor (EGFR) have shown clinical
benefit in a subset of non–small cell lung cancer patients expressing amplified or …

Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have
shown dramatic effects against EGFR mutant lung cancer, patients become resistant by …

Introduction Despite an initial dramatic response to the epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, the majority of non–small cell …